What is the current valuation of the Italy fertility drug-surgery market as of 2024?

The market valuation was $75.75 Million in 2024. Read More

What is the projected market valuation for the Italy fertility drug-surgery market in 2035?

The projected valuation for 2035 is $148.25 Million. Read More

What is the expected CAGR for the Italy fertility drug-surgery market during the forecast period 2025 - 2035?

The expected CAGR during this period is 6.29%. Read More

Which companies are the key players in the Italy fertility drug-surgery market?

Key players include Ferring Pharmaceuticals, Merck KGaA, Bayer AG, AbbVie Inc., Eli Lilly and Company, SAGE Therapeutics, HRA Pharma, and Irvine Scientific. Read More

What are the main segments of the Italy fertility drug-surgery market?

The main segments include Underlying Cause, Drug, Procedures, and End-User. Read More

What was the market value for male and female fertility treatments in the Underlying Cause segment?

The market values were $30.0 Million for male and $45.75 Million for female treatments. Read More

What are the leading drugs in the Italy fertility drug-surgery market and their valuations?

Leading drugs include Clomiphene Citrate at $10.0 - $20.0 Million and Gonadotrophins at $15.0 - $30.0 Million. Read More

What surgical procedures are included in the Italy fertility drug-surgery market?

Included procedures are Hysteroscopy, Laparoscopy, Laparotomy, Egg Retrieval, and Varicocelectomy. Read More

What is the market value for fertility clinics and hospitals as end-users in this market?

Fertility clinics are valued at $30.0 - $60.0 Million, while hospitals are valued at $25.0 - $50.0 Million. Read More

How does the market for fertility drugs compare to surgical procedures in terms of valuation?

The drug segment shows higher valuations, with Hormone Treatment valued at $12.0 - $25.0 Million, compared to surgical procedures like Egg Retrieval valued at $12.0 - $25.0 Million. Read More

Italy Fertility Drug Surgery Market

ID: MRFR/Pharma/52252-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

Italy Fertility Drug Surgery Market Research Report By Underlying Cause (Male, Female), By Drugs (Clomiphene Citrate, Letrozole), By Procedures (Hysteroscopy, Laparoscopy, Robotic Laparoscopy) and By End User (Fertility Clinics) -Forecast to 2035

Italy Fertility Drug Surgery Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Underlying Cause (USD Million)
  1. 4.1.1 Male
  2. 4.1.2 Female
2. 4.2 Life Sciences, BY Drug (USD Million)
  1. 4.2.1 Clomiphene Citrate
  2. 4.2.2 Letrozole
  3. 4.2.3 Serophene
  4. 4.2.4 Hormone Treatment
  5. 4.2.5 Gonadotrophins
  6. 4.2.6 Aromatase Inhibitors
  7. 4.2.7 Estrogen Receptor Modulators
  8. 4.2.8 Dopamine Agonists
  9. 4.2.9 Metformin Hydrochloride
  10. 4.2.10 Others
3. 4.3 Life Sciences, BY Procedures (USD Million)
  1. 4.3.1 Hysteroscopy
  2. 4.3.2 Laparoscopy and Robotic Laparoscopy
  3. 4.3.3 Laparotomy/Open Surgery
  4. 4.3.4 Egg Retrieval
  5. 4.3.5 Varicocelectomy
  6. 4.3.6 Vasectomy Reversal
  7. 4.3.7 Sperm Retrieval
4. 4.4 Life Sciences, BY End-User (USD Million)
  1. 4.4.1 Fertility Clinics
  2. 4.4.2 Hospitals
  3. 4.4.3 Clinical Research Institutes
  4. 4.4.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Ferring Pharmaceuticals (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bayer AG (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie Inc. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 SAGE Therapeutics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 HRA Pharma (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Irvine Scientific (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 ITALY MARKET ANALYSIS BY UNDERLYING CAUSE
3. 6.3 ITALY MARKET ANALYSIS BY DRUG
4. 6.4 ITALY MARKET ANALYSIS BY PROCEDURES
5. 6.5 ITALY MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY UNDERLYING CAUSE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY UNDERLYING CAUSE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY DRUG, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY DRUG, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY PROCEDURES, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY PROCEDURES, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY UNDERLYING CAUSE, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG, 2025-2035 (USD Million)
  3. 7.2.3 BY PROCEDURES, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Italy Life Sciences Market Segmentation

Life Sciences By Underlying Cause (USD Million, 2025-2035)

Male
Female

Life Sciences By Drug (USD Million, 2025-2035)

Clomiphene Citrate
Letrozole
Serophene
Hormone Treatment
Gonadotrophins
Aromatase Inhibitors
Estrogen Receptor Modulators
Dopamine Agonists
Metformin Hydrochloride
Others

Life Sciences By Procedures (USD Million, 2025-2035)

Hysteroscopy
Laparoscopy and Robotic Laparoscopy
Laparotomy/Open Surgery
Egg Retrieval
Varicocelectomy
Vasectomy Reversal
Sperm Retrieval

Life Sciences By End-User (USD Million, 2025-2035)

Fertility Clinics
Hospitals
Clinical Research Institutes
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”